In addition, Rolih et al. systematically summarized the evidence of CSPG4 in tumor biology and suggested that CSPG4 and anti-CSPG4 vaccination strategy had the potential to be an attractive target for anti-tumor immunotherapy (Rolih et al., 2017). This evidence concerns the gene CSPG4 and neoplasm.